Literature DB >> 29533918

Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.

Paul Mel van Dam1, Mark Wl van Geffen1, Thomas Ra Havenith2, Dirk Posthouwer1.   

Abstract

Triumeq is a single-tablet regimen for patients with HIV infection comprising dolutegravir, abacavir and lamivudine. Overdoses with Triumeq have not been reported previously. We present a case of a 26-year-old man who presented to our hospital after intentionally ingesting 30 tablets of Triumeq. An intoxication with Triumeq can lead to several side effects. An overdose of abacavir and lamivudine can cause mitochondrial toxicity and lactic acidosis. An intoxication with dolutegravir appears to be relatively harmless. As Triumeq will be used on a regular basis as treatment for patients with HIV-1 infection, these intoxications are expected to be encountered more often.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29533918     DOI: 10.3851/IMP3229

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535            Impact factor:   1.679


  3 in total

1.  Paediatric antiretroviral overdose: A case report from a resource-poor area.

Authors:  Bryan A Ogoti; Angela A Otedo; Thomas M Chokwe
Journal:  South Afr J HIV Med       Date:  2020-07-21       Impact factor: 2.744

2.  Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient.

Authors:  Muhammad Saad; Fernando Casado-Castillo; Paul Kelly
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

Review 3.  Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature.

Authors:  Alexa Hollinger; Nadine Cueni; Martin Siegemund; Anne Leuppi-Taegtmeyer; Catia Marzolini; Michael Dickenmann; Emmanuelle Landmann; Manuel Battegay; Aurélien Emmanuel Martinez
Journal:  AIDS Res Ther       Date:  2021-09-04       Impact factor: 2.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.